Safety Study of KUP-101A in Advanced Solid Tumors
Part of Cancer, Skin clinical trials.
This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be advanced and confirmed by a biopsy, with no other standard treatment options available
- You must be in reasonably good overall health (able to do light activity or rest most of the day)
- Your liver, kidneys, and blood counts must be working well enough
- You cannot have had previous immune-activating drugs (TLR agonists) except as part of a vaccine
- You cannot have an active autoimmune disease or immunodeficiency disorder
- You cannot have cancer that has spread to your brain or leukemia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
This trial is testing a new drug, MK-2010, alone or with other treatments for people with advanced solid tumors. The goal is to learn if it is safe and effective. Participants should be in fairly good health despite their cancer.
This trial tests a new drug called SC-101 in people with advanced solid tumors that have not responded to other treatments. It may be an option if your tumor shows a specific protein called Nectin-4, which the drug targets.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.